S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
ETR:EVT

Evotec (EVT) Stock Price, News & Analysis

€14.38
+0.61 (+4.43%)
(As of 03/27/2024 ET)
Today's Range
€13.76
€14.45
50-Day Range
€12.62
€15.28
52-Week Range
€12.61
€24.44
Volume
714,193 shs
Average Volume
1.36 million shs
Market Capitalization
$2.55 billion
P/E Ratio
N/A
Dividend Yield
2.63%
Price Target
€21.00

Evotec MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
46.1% Upside
€21.00 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.35 out of 5 stars

EVT stock logo

About Evotec Stock (ETR:EVT)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

EVT Stock Price History

EVT Stock News Headlines

Evotec-Aktie: Das wird spannend
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
Evotec: Aktie fällt und fällt - das ist jetzt wichtig
Evotec SE: Invitation to Conference Call
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
EQS-Adhoc: Evotec announces CEO transition
Evotec SE: Evotec Announces CEO Transition
EQS-News: Evotec announces CEO transition
Evotec Announces CEO Transition
EQS-News: Evotec-partner Jingxin receives approval for EVT201 in China
See More Headlines
Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
5,086
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
€21.00
High Stock Price Target
€21.00
Low Stock Price Target
€21.00
Potential Upside/Downside
+46.1%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-94,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$820.80 million
Cash Flow
€4.16 per share
Book Value
€6.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.55 billion
Optionable
Not Optionable
Beta
1.09
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Mario Polywka DPHIL (Age 61)
    Ph.D., Interim CEO, Member of the Management Board & Member of the Supervisory Board
  • Dr. Werner Lanthaler M.B.A. (Age 56)
    MPA, Ph.D., Member of Management Board
    Comp: $1.32M
  • Dr. Cord Dohrmann Ph.D. (Age 60)
    Chief Scientific Officer & Member of Management Board
    Comp: $804k
  • Dr. Craig Johnstone Ph.D. (Age 54)
    COO & Member of Management Board
    Comp: $712k
  • Dr. Matthias Evers Ph.D. (Age 51)
    Chief Business Officer & Member of Management Board
    Comp: $636k
  • Ms. Laetitia Rouxel (Age 50)
    CFO & Member of Management Board
  • Ms. Anja Bosler
    Principal Accounting Officer and Senior Vice President of Group Accounting
  • Mr. Volker Braun
    Senior VP and Global Head of Investor Relations & ESG
  • Dr. Christian Dargel
    EVP Global Head of Legal & Compliance
  • Gabriele Hansen
    Senior VP & Head of Global Corporate Communications & Marketing

EVT Stock Analysis - Frequently Asked Questions

What is Evotec's stock price target for 2024?

0 Wall Street analysts have issued 1-year price targets for Evotec's shares. Their EVT share price targets range from €21.00 to €21.00. On average, they predict the company's stock price to reach €21.00 in the next year. This suggests a possible upside of 46.1% from the stock's current price.
View analysts price targets for EVT
or view top-rated stocks among Wall Street analysts.

How have EVT shares performed in 2024?

Evotec's stock was trading at €21.28 at the start of the year. Since then, EVT shares have decreased by 32.4% and is now trading at €14.38.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

This page (ETR:EVT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners